Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil for microvascular dysfunction in acute myocardial infarction undergoing primary PCI
ChiCTR2200061692Phase 4Recruiting
- Sponsor
- Shanxi Provincial People's Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nicorandil in myocardial infarction (MI) and coronary arteriosclerosis (2 arms), sponsored by Shanxi Provincial People's Hospital. Primary endpoints: TIMI blood flow classification, Index of microcirculation resistance (IMR) and 2 more. Started Mar 2017; status: recruiting.
02
Drugs
nicorandil
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200061692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061692.